Schubart CD, Sommer IE, Fusar-Poli P, de Witte L, Kahn RS, Boks MP.
Although cannabis use is associated with an increased risk of developing
psychosis, the cannabis constituent cannabidiol (CBD) may have
antipsychotic properties. This review concisely describes the role of
the endocannabinoid system in the development of psychosis and provides
an overview of currently available animal, human experimental, imaging,
epidemiological and clinical studies that investigated the antipsychotic
properties of CBD. In this targeted literature review we performed a
search for English articles using Medline and EMBASE. Studies were
selected if they described experiments with psychosis models, psychotic
symptoms or psychotic disorders as outcome measure and involved the use
of CBD as intervention. Evidence from several research domains suggests
that CBD shows potential for antipsychotic treatment.